Extracellular vesicles, or EVs, are small lipid-enclosed particles released by virtually every cell type in the body, including tumor cells. For decades they were dismissed as cellular debris, but they are now recognized as a fundamental communication system: EVs ferry proteins, lipids and nucleic acids between cells, influencing processes such as immune regulation, angiogenesis and metastatic preparation. Because the molecular cargo of an EV reflects the cell that released it, tumor-derived vesicles are increasingly viewed as a liquid biopsy window into the biology of a cancer without the need for invasive tissue sampling. Cytokines, the small proteins that immune and stromal cells use to signal to one another, are known to shape tumor development and progression, and the question driving this study was whether cytokines bound to or packaged within EVs form a measurable and clinically informative signature in the bloodstream.

To answer it, the researchers isolated EVs from plasma using ultracentrifugation, a technique that spins samples at extremely high speeds to pellet vesicles out of solution. They applied a rigorous characterization pipeline to confirm that the particles they recovered were genuine EVs: transmission electron microscopy provided direct visualization of vesicle morphology, nanoparticle tracking analysis quantified particle size and concentration, flow cytometry probed surface markers, and western blotting verified the presence of canonical EV-associated proteins. The same isolation approach was applied to breast cell lines grown in the laboratory, giving the team a controlled comparison against vesicles produced by healthy breast tissue cells.

The clinical core of the study involved 46 patients with ER+ breast cancer enrolled in the Neoletexe trial, alongside 13 healthy individuals as controls. EV-associated cytokines were profiled using a Luminex multiplex assay, a bead-based platform capable of measuring dozens of proteins simultaneously from a small sample volume. Crucially, the researchers sampled patients at three timepoints: before treatment began (T0), and at two points during neoadjuvant endocrine therapy (T1 and T2). This longitudinal design meant that each patient could serve partly as her own control, revealing how the vesicle-bound cytokine landscape shifted as aromatase inhibitors stripped estrogen from the equation and the tumor responded, or failed to respond, to the hormonal blockade.

The headline finding was that three EV-associated cytokines were significantly elevated in ER+ breast cancer patients compared with healthy individuals: interleukin 10 (IL-10), interleukin 12 (IL-12) and interferon gamma inducible protein 10, better known as IP-10 or CXCL10. Each of these molecules carries immunological weight. IL-10 is generally an anti-inflammatory cytokine that can dampen immune attacks on tumors, IL-12 is a potent activator of T cells and natural killer cells, and IP-10 is a chemokine recruited into action by interferon gamma that guides immune cells to sites of inflammation and, in many cancers, is intertwined with the tumor microenvironment’s immune landscape. Their enrichment on circulating vesicles in patients suggests that EV-associated cytokines capture disease-relevant immune signaling that differs measurably from the healthy state.

The IP-10 result gained independent support from tumor tissue analysis. Using gene expression data, the team found that CXCL10, the gene encoding IP-10, was overexpressed in breast cancer tissue relative to both normal and benign breast tissue, a pattern corroborated through the GEPIA analysis platform drawing on The Cancer Genome Atlas. This convergence between the vesicle protein measurements in blood and the transcriptional activity inside tumors strengthens the argument that EV-associated IP-10 genuinely reflects processes occurring at the disease site rather than incidental background variation. It is exactly this kind of cross-validation that candidate biomarkers need before they can move from exploratory science toward clinical utility.

Perhaps the most technically interesting result concerned how the vesicle-bound cytokines behaved once endocrine therapy started. Levels of EV-associated IL-10 and IL-12 decreased significantly during NET, indicating that the treatment does not merely shrink or slow the tumor but measurably reshapes the immune signaling carried by circulating vesicles. Notably, the treatment-associated changes were more pronounced in the EV-associated cytokines than in the corresponding free-circulating cytokines measured in the same plasma samples, and more pronounced than changes in cytokine gene expression measured in tumor tissue from a subset of the same patients. This suggests that vesicle-packaged cytokines act as a kind of amplifier or concentrator of systemic immune signals, potentially offering greater analytical sensitivity than conventional plasma cytokine assays, which have long been hampered by low concentrations, short half-lives and interference from non-specific binding.

The study was not without its sobering results. When the researchers asked whether any of the measured cytokines predicted treatment response, as assessed by the change in Ki-67, the standard proliferation marker used to gauge how actively tumor cells are dividing under therapy, only eotaxin, a chemokine best known for recruiting eosinophils, showed a significant association. None of the three disease-elevated cytokines tracked treatment response in this way. This dissociation between disease detection and response prediction is an important nuance: a marker can be excellent at distinguishing patients from healthy individuals yet still fail to forecast how an individual tumor will behave under therapy. The authors are careful to frame their findings as evidence that EV-associated cytokines reflect disease- and treatment-related changes, while emphasizing that further studies are required to determine their potential clinical relevance as biomarkers.

Methodologically, the study demonstrates the value of triangulating across molecular compartments. By measuring the same cytokines in three formats, vesicle-bound in plasma, free-circulating in plasma, and as gene expression in tumor tissue, the researchers could show that the vesicle fraction carries complementary rather than redundant information. This matters because the field of liquid biopsy has often been dominated by circulating tumor DNA and extracellular RNA, while the protein cargo of EVs, and cytokines in particular, has remained comparatively underexplored. The finding that EV-associated signals respond more dynamically to endocrine therapy than either free cytokines or tumor transcript levels hints that vesicles may stabilize and enrich labile signaling proteins, protecting them from degradation and protease activity in the bloodstream.

The broader implications reach into how ER-positive breast cancer is monitored. Neoadjuvant endocrine therapy is typically given for months before surgery, and clinicians currently rely on imaging and serial biopsies to judge whether the regimen is working. A blood test that captures treatment-induced shifts in tumor-associated immune signaling could, if validated, allow earlier and less invasive assessment. The Norwegian team’s work, funded in part by Akershus University Hospital and the Norwegian Breast Cancer Research Network and conducted under ethical approval from the Regional Ethics Committee of Southeast Norway, provides a carefully characterized early step in that direction. With 46 patients and 13 controls, the cohort is modest, and ultracentrifugation-based EV isolation, while thorough, is labor-intensive and not yet standardized across laboratories. Larger, multi-center studies with standardized vesicle isolation and longitudinal follow-up will be needed to establish whether IL-10, IL-12 and IP-10 on circulating vesicles can graduate from candidate markers to clinically actionable tools. For now, the study adds a compelling piece to the growing evidence that the smallest messengers in our blood may carry some of the biggest clues about cancer.

Subject of Research: Extracellular vesicle-associated cytokines as circulating biomarkers in ER-positive breast cancer and neoadjuvant endocrine therapy

Article Title: Analysis of circulatory extracellular vesicle–associated cytokines as candidate disease-associated markers in ER-positive breast cancer

Article References: Huynh, H. M., Nawaz, M. S., Jabeen, S., Bjørnetrø, T., Geisler, J., Kristensen, V., & Tahiri, A. (2026). Analysis of circulatory extracellular vesicle–associated cytokines as candidate disease-associated markers in ER-positive breast cancer. BMC Cancer. https://doi.org/10.1186/s12885-026-17052-5

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17052-5

Keywords: extracellular vesicles, cytokines, ER-positive breast cancer, liquid biopsy, biomarkers, neoadjuvant endocrine therapy, IL-10, IL-12, IP-10, CXCL10, aromatase inhibitors, Neoletexe trial

The study, published in the Journal of Cancer Research and Clinical Oncology, set out to answer a deceptively simple question. If natural killer cells are to be used as a living drug against oesophagogastric adenocarcinoma, a cancer whose incidence is rising steeply in parallel with obesity, will they still work once they arrive in the patient’s body? The tumour microenvironment is a chemically hostile neighbourhood, saturated with immunosuppressive metabolites, cytokines and lipids, and in patients with obesity the omentum, a fatty apron of visceral adipose tissue draped over the abdominal organs, adds its own inflammatory and lipid-rich milieu. Any adoptive cell therapy must not only survive these conditions but also navigate them, migrating to the tumour rather than being lured elsewhere.

To model this terrain in the laboratory, the researchers collected tissue from patients undergoing surgery for oesophagogastric adenocarcinoma and prepared conditioned media, nutrient-rich fluids in which pieces of tumour or omental adipose tissue had been cultured. These adipose-conditioned media and tumour-conditioned media recapitulate the soluble cocktail of signalling molecules, chemokines, fatty acids and metabolites that a therapeutic cell would encounter in vivo. The team then bathed KHYG-1 cells in these fluids and measured what happened to their phenotype and function using flow cytometry, a technique that reads the fluorescent signatures of proteins on and inside individual cells.

The central finding was one of resilience. Neither the adipose-conditioned media nor the tumour-conditioned media derived from patients with obesity significantly suppressed the effector function of KHYG-1 cells. In other words, the cells’ capacity to kill was not meaningfully blunted by the soluble factors secreted by either the fat or the tumour. This stands in contrast to the well-documented dysfunction seen in natural killer cells taken from the blood and tissues of patients with obesity and cancer, and it suggests that KHYG-1 cells, an immortalised human natural killer cell line widely used as a research model and a candidate for cellular therapy, carry an intrinsic resistance to the immunosuppressive pressures of this disease setting.

Intriguingly, the study also found that exposure to the conditioned media altered the expression of phenotypic and functional markers on the KHYG-1 cells, and that adipose-conditioned media actually increased their killing capacity. Rather than being worn down by the fatty environment, the cells appeared in some respects to be primed by it. The researchers compared KHYG-1 cells with natural killer cells derived from the peripheral blood of healthy donors, providing a benchmark against which the cell line’s robustness could be judged. The comparison matters because blood-derived natural killer cells are the more conventional starting material for adoptive cell therapy, and their known susceptibility to obesity-associated dysfunction is precisely the problem a cell line such as KHYG-1 might sidestep.

Function, however, is only half the battle. A therapeutic cell that cannot find the tumour is a weapon without a target. The team therefore tested whether KHYG-1 cells could migrate towards the chemical signals emanating from omental fat and tumour tissue, using a Boyden chamber assay, a classic technique in which cells are placed in an upper chamber and their movement through a membrane towards chemoattractants in a lower chamber is counted. The result was a cautionary one. KHYG-1 cells migrated in significantly higher numbers towards the chemotactic signals of the omentum than towards those of the tumour. In a patient’s abdomen, where the omentum lies in close anatomical proximity to oesophagogastric tumours, this bias could draw therapeutic cells into fat tissue rather than into the malignancy they are meant to attack.

This migratory misdirection is not a trivial technicality. Obesity-associated cancers arise in a landscape where visceral adipose tissue is abundant, and the chemokine gradients produced by omental fat can act as siren songs for immune cells. The Dublin group’s data suggest that erroneous homing towards the omentum would present a genuine challenge for the effective delivery of KHYG-1 cells to oesophagogastric tumours in living patients. Yet the study did not stop at identifying the problem; it also pointed towards a solution rooted in the chemistry of attraction.

When the researchers supplemented the tumour-conditioned media with IP-10, a chemokine also known as interferon-gamma-inducible protein 10 that is naturally produced during inflammatory responses and is known to attract natural killer cells through the CXCR3 receptor, the chemoattraction of KHYG-1 cells to the tumour environment increased. This proof-of-principle experiment supports the concept of chemokine profile remodelling: deliberately reshaping the signalling landscape of the tumour microenvironment so that therapeutic cells are guided towards the cancer rather than into the surrounding fat. Such remodelling could be achieved through local delivery of chemokines, oncolytic viral vectors engineered to secrete attractants, or other strategies that physicians and bioengineers are already exploring in related contexts.

The broader significance of the work lies in its ex vivo rigour. By using patient-derived materials rather than simplified cell culture systems, the study captured a realistic snapshot of the obesity-associated cancer environment, and by testing both function and migration it addressed the two properties that determine whether adoptive cell therapy can succeed. Oesophagogastric adenocarcinoma carries a poor prognosis, and patients with obesity face compounded immunological disadvantages, making the search for effective immunotherapies in this population particularly urgent. The findings suggest that KHYG-1 cells, or cell lines and engineered derivatives modelled on them, could form the basis of therapies that augment anti-tumour immunity where the patient’s own natural killer cells have faltered.

Considerable work remains before any clinical translation. The experiments were conducted outside the body, and the full complexity of the in vivo environment, including vascular trafficking, stromal barriers and interactions with other immune populations, cannot be fully reproduced in a dish. The authors themselves emphasise that the migratory bias towards omentum will need to be overcome, likely through the chemokine-remodelling approaches their data support. Nonetheless, the study offers a dual gift to the field: evidence that a candidate therapeutic cell can retain its cytotoxic potency in one of the most immunologically challenging disease settings, and a mechanistically grounded roadmap for steering those cells to where they are needed most. For a cancer whose burden grows with the global obesity epidemic, that combination of resilience and navigability may prove to be exactly what the next generation of natural killer cell therapies requires.

Subject of Research: The functional resilience and migratory behaviour of KHYG-1 natural killer cells in the tumour and omental microenvironments of obesity-associated oesophagogastric adenocarcinoma.

Article Title: KHYG-1 cells retain functionality following exposure to the tumour and omental microenvironments of patients with obesity-associated cancer

Article References: Marion, C., Barry, J. C., Mylod, E., Smith, L., Menon, M. S., O’Connor, N., Butler, C., Deac, O. M., Donohoe, C. L., Elliott, J. A., Lowery, M., Reynolds, J. V., Lysaght, J., & Conroy, M. J. (2026). KHYG-1 cells retain functionality following exposure to the tumour and omental microenvironments of patients with obesity-associated cancer. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06617-3

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06617-3

Keywords: natural killer cells, KHYG-1, oesophagogastric adenocarcinoma, obesity, tumour microenvironment, omentum, chemokines, IP-10, cell migration, immunotherapy, cancer research, adoptive cell therapy